Inpatient Closed-loop Glucose Control
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 21 - 80 |
| Updated: | 12/14/2017 |
| Start Date: | March 2013 |
| End Date: | December 2014 |
Subcutaneous Continuous Glucose Monitoring and Intravenous Dosing of Insulin and Dextrose for Automated Glycemic Control in the Inpatient Setting
The purpose of this study is to test an experimental medical device designed to automatically
control blood sugar. This device was designed for use by patients with diabetes while they
are in the hospital, and others who may develop high blood sugar as a result of their medical
problems.
control blood sugar. This device was designed for use by patients with diabetes while they
are in the hospital, and others who may develop high blood sugar as a result of their medical
problems.
The goal of this first-in-man trial is to test the safety and efficacy of the automated,
closed-loop control system in insulin sensitive subjects with type 1 diabetes, insulin
sensitive subjects with type 2 diabetes (TTD > 1u/kg/day), and subjects with type 2 diabetes
and substantial insulin resistance (<2 u/kg/day). The results of this study will help to
design future studies, exploring the use of the closed-loop system for BG control in
hospitalized patients, including those with diabetes or hyperglycemia of critical illness.
closed-loop control system in insulin sensitive subjects with type 1 diabetes, insulin
sensitive subjects with type 2 diabetes (TTD > 1u/kg/day), and subjects with type 2 diabetes
and substantial insulin resistance (<2 u/kg/day). The results of this study will help to
design future studies, exploring the use of the closed-loop system for BG control in
hospitalized patients, including those with diabetes or hyperglycemia of critical illness.
Inclusion Criteria
Subjects with type 1 diabetes
- Age 21 to 75 with clinical type 1 diabetes for at least one year
- Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting
insulins
- Total daily dose (TDD) of insulin that is < 1 u/kg
Subjects with type 2 diabetes
- Age 21 to 75 with clinical type 2 diabetes for at least one year
- Diabetes managed using NPH as the basal insulin, which may be supplemented with
regular or rapid-acting insulin
- Total daily dose (TDD) of insulin that is > 1 u/kg/day but < 2 u/kg/day or > 2
u/kg/day
Exclusion Criteria:
- Pregnancy
- Renal insufficiency
- Cancer
- Abnormal EKG suggestive of coronary artery disease or increased risk of malignant
arrhythmia
- Acute illness or exacerbation of chronic illness at the time of the study procedure
- Use of non-insulin, injectable anti-diabetic medications or oral anti-diabetic
medications other than metformin
- History of allergy or adverse reaction to aspirin, peptic ulcers or bleeding disorders
- Known history of coronary artery disease, TIA or stroke
- History of seizures
- Transaminitis
- Stage 2 hypertension at the time of screening
We found this trial at
1
site
Click here to add this to my saved trials
